Test-Retest Reliability of the Patient Activation Measure-13 in Adults with Substance Use Disorders and Schizophrenia Spectrum Disorders

Katrine Melby, Mona Nygård, Mathias Forsberg Brobakken, Rolf W Gråwe, Ismail Cüneyt Güzey, Solveig Klæbo Reitan, Einar Vedul-Kjelsås, Jørn Heggelund, Mariela Loreto Lara-Cabrera, Katrine Melby, Mona Nygård, Mathias Forsberg Brobakken, Rolf W Gråwe, Ismail Cüneyt Güzey, Solveig Klæbo Reitan, Einar Vedul-Kjelsås, Jørn Heggelund, Mariela Loreto Lara-Cabrera

Abstract

Patient Activation Measure-13 (PAM-13) is a valid and widely used questionnaire that assess an individual's knowledge, confidence, and skills for self-management of their chronic illness. Although there is some evidence regarding its reliability, the test-retest reliability has not been investigated among patients with substance use disorders (SUDs) or schizophrenia spectrum disorders. We investigated the internal consistency and test-retest reliability of PAM-13 in these populations. Test-retest reliability was analysed using data from 29 patients with SUDs and 28 with schizophrenia spectrum disorders. Cronbach's α and Intraclass Correlation Coefficient (ICC) scores were used to examine internal consistency and test-retest reliability, respectively. Of the 60 collected test-retest questionnaires, 57 were included in the analyses. No mean differences between time one (T1) and time two (T2) were observed in either patient group, except for item 12 in schizophrenia spectrum disorders patients (p < 0.05). Internal consistency for T1 and T2 was 0.75 and 0.84 in SUDs patients and 0.87 and 0.81 in schizophrenia spectrum disorders patients, respectively. The ICC was r = 0.86 in patients with SUDs and r = 0.93 in patients with schizophrenia spectrum disorders. To conclude, PAM-13 showed good internal consistency and test-retest reliability in SUDs and schizophrenia spectrum disorders patients.

Keywords: internal consistency; patient activation measure-13; schizophrenia spectrum disorders; self-management; substance use disorder; test–retest reliability.

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

    1. Vossius C., Testad I., Skjaeveland R., Nesvag S. The use and costs of health and social services in patients with longstanding substance abuse. BMC Health Serv. Res. 2013;13:185. doi: 10.1186/1472-6963-13-185.
    1. Jin H., Mosweu I. The Societal Cost of Schizophrenia: A Systematic Review. Pharmacoeconomics. 2017;35:25–42. doi: 10.1007/s40273-016-0444-6.
    1. Brorson H.H., Arnevik E.A., Rand-Hendriksen K., Duckert F. Drop-out from addiction treatment: A systematic review of risk factors. Clin. Psychol. Rev. 2013;33:1010–1024. doi: 10.1016/j.cpr.2013.07.007.
    1. Gunatilake S., Ananth J., Parameswaran S., Brown S., Silva W. Rehabilitation of schizophrenic patients. Curr. Pharm. Des. 2004;10:2277–2288. doi: 10.2174/1381612043384141.
    1. Davoli M., Bargagli A.M., Perucci C.A., Schifano P., Belleudi V., Hickman M., Salamina G., Diecidue R., Vigna-Taglianti F., Faggiano F. Risk of fatal overdose during and after specialist drug treatment: The VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102:1954–1959. doi: 10.1111/j.1360-0443.2007.02025.x.
    1. Nordentoft M., Wahlbeck K., Hallgren J., Westman J., Osby U., Alinaghizadeh H., Gissler M., Laursen T.M. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS ONE. 2013;8:e55176. doi: 10.1371/journal.pone.0055176.
    1. Hibbard J.H., Stockard J., Mahoney E.R., Tusler M. Development of the Patient Activation Measure (PAM): Conceptualizing and measuring activation in patients and consumers. Health Serv. Res. 2004;39:1005–1026. doi: 10.1111/j.1475-6773.2004.00269.x.
    1. Hibbard J.H., Greene J. What the evidence shows about patient activation: Better health outcomes and care experiences; fewer data on costs. Health Aff. 2013;32:207–214. doi: 10.1377/hlthaff.2012.1061.
    1. Kinney R.L., Lemon S.C., Person S.D., Pagoto S.L., Saczynski J.S. The association between patient activation and medication adherence, hospitalization, and emergency room utilization in patients with chronic illnesses: A systematic review. Patient Educ. Couns. 2015;98:545–552. doi: 10.1016/j.pec.2015.02.005.
    1. Hibbard J.H., Mahoney E.R., Stockard J., Tusler M. Development and testing of a short form of the patient activation measure. Health Serv. Res. 2005;40:1918–1930. doi: 10.1111/j.1475-6773.2005.00438.x.
    1. Begum N., Donald M., Ozolins I.Z., Dower J. Hospital admissions, emergency department utilisation and patient activation for self-management among people with diabetes. Diabetes Res. Clin. Pract. 2011;93:260–267. doi: 10.1016/j.diabres.2011.05.031.
    1. Skolasky R.L., Mackenzie E.J., Riley L.H., 3rd, Wegener S.T. Psychometric properties of the Patient Activation Measure among individuals presenting for elective lumbar spine surgery. Qual. Life Res. 2009;18:1357–1366. doi: 10.1007/s11136-009-9549-0.
    1. Rademakers J., Nijman J., van der Hoek L., Heijmans M., Rijken M. Measuring patient activation in The Netherlands: Translation and validation of the American short form Patient Activation Measure (PAM13) BMC Public Health. 2012;12:577. doi: 10.1186/1471-2458-12-577.
    1. Moljord I.E., Lara-Cabrera M.L., Perestelo-Perez L., Rivero-Santana A., Eriksen L., Linaker O.M. Psychometric properties of the Patient Activation Measure-13 among out-patients waiting for mental health treatment: A validation study in Norway. Patient Educ. Couns. 2015;98:1410–1417. doi: 10.1016/j.pec.2015.06.009.
    1. Bomba F., Markwart H., Muhlan H., Menrath I., Ernst G., Thyen U., Schmidt S. Adaptation and validation of the German Patient Activation Measure for adolescents with chronic conditions in transitional care: PAM((R)) 13 for Adolescents. Res. Nurs. Health. 2018;41:78–87. doi: 10.1002/nur.21831.
    1. Kosar C., Besen D.B. Adaptation of a patient activation measure (PAM) into Turkish: Reliability and validity test. Afr. Health Sci. 2019;19:1811–1820. doi: 10.4314/ahs.v19i1.58.
    1. Cunha C.M., da Cunha D., Manzato R.O., Nepomuceno E., da Silva D., Dantas R.A.S. Validation of the Brazilian Version of the Patient Activation Measure 13. J. Nurs. Meas. 2019;27:97–113. doi: 10.1891/1061-3749.27.1.97.
    1. Hellstrom A., Kassaye Tessma M., Flink M., Dahlgren A., Schildmeijer K., Ekstedt M. Validation of the patient activation measure in patients at discharge from hospitals and at distance from hospital care in Sweden. BMC Public Health. 2019;19:1701. doi: 10.1186/s12889-019-8025-1.
    1. Bahrom N.H., Ramli A., Isa M., Baharudin N., Badlishah-Sham S., Mohamed-Yassin M., Abdul-Hamid H. Validity and reliability of the Patient Activation Measure®(PAM®)-13 Malay version among patients with Metabolic Syndrome in primary care. Malays. Fam. Phys. 2020;15:22.
    1. Kukla M., Salyers M.P., Lysaker P.H. Levels of patient activation among adults with schizophrenia: Associations with hope, symptoms, medication adherence, and recovery attitudes. J. Nerv. Ment. Dis. 2013;201:339–344. doi: 10.1097/NMD.0b013e318288e253.
    1. Salyers M.P., Matthias M.S., Spann C.L., Lydick J.M., Rollins A.L., Frankel R.M. The role of patient activation in psychiatric visits. Psychiatr. Serv. 2009;60:1535–1539. doi: 10.1176/ps.2009.60.11.1535.
    1. Moljord I., Lara-Cabrera M., Salvesen Ø., Rise M., Bjørgen D., Antonsen D., Olsø T., Evensen G., Gudde C., Linaker O. Twelve months effect of self-referral to inpatient treatment on patient activation, recovery, symptoms and functioning: A randomized controlled study. Patient Educ. Couns. 2017;100:1144–1152. doi: 10.1016/j.pec.2017.01.008.
    1. Lara-Cabrera M.L., Salvesen Ø., Nesset M.B., De las Cuevas C., Iversen V.C., Gråwe R.W. The effect of a brief educational programme added to mental health treatment to improve patient activation: A randomized controlled trial in community mental health centres. Patient Educ. Couns. 2016;99:760–768. doi: 10.1016/j.pec.2015.11.028.
    1. Druss B.G., Singh M., von Esenwein S.A., Glick G.E., Tapscott S., Tucker S.J., Lally C.A., Sterling E.W. Peer-Led Self-Management of General Medical Conditions for Patients With Serious Mental Illnesses: A Randomized Trial. Psychiatr. Serv. 2018;69:529–535. doi: 10.1176/appi.ps.201700352.
    1. Young J.T., Heffernan E., Borschmann R., Ogloff J.R.P., Spittal M.J., Kouyoumdjian F.G., Preen D.B., Butler A., Brophy L., Crilly J., et al. Dual diagnosis of mental illness and substance use disorder and injury in adults recently released from prison: A prospective cohort study. Lancet Public Health. 2018;3:e237–e248. doi: 10.1016/S2468-2667(18)30052-5.
    1. Bujang M.A., Baharum N. A simplified guide to determination of sample size requirements for estimating the value of intraclass correlation coefficient: A review. J. Orofac Sci. 2017;12:1–11.
    1. Mokkink L.B., Prinsen C., Patrick D.L., Alonso J., Bouter L.M., de Vet H., Terwee C.B., Mokkink L. COSMIN methodology for systematic reviews of patient-reported outcome measures (PROMs) User Man. 2018;78:1.
    1. Kim S., Kim E., Ryu E. Illness Perceptions, Self-Care Management, and Clinical Outcomes According to Age-Group in Korean Hemodialysis Patients. Int. J. Environ. Res. Public Health. 2019;16:4459. doi: 10.3390/ijerph16224459.
    1. Keszei A.P., Novak M., Streiner D.L. Introduction to health measurement scales. J. Psychosom. Res. 2010;68:319–323. doi: 10.1016/j.jpsychores.2010.01.006.
    1. Flemmen G., Wang E. Impaired Aerobic Endurance and Muscular Strength in Substance Use Disorder Patients: Implications for Health and Premature Death. Medicine. 2015;94:e1914. doi: 10.1097/MD.0000000000001914.
    1. Mosti M.P., Flemmen G., Hoff J., Stunes A.K., Syversen U., Wang E. Impaired skeletal health and neuromuscular function among amphetamine users in clinical treatment. Osteoporos. Int. 2016;27:1003–1010. doi: 10.1007/s00198-015-3371-z.
    1. Brobakken M.F., Nygard M., Taylor J.L., Guzey I.C., Morken G., Reitan S.K., Heggelund J., Vedul-Kjelsaas E., Wang E. A comprehensive cardiovascular disease risk profile in patients with schizophrenia. Scand. J. Med. Sci. Sports. 2019 doi: 10.1111/sms.13371.
    1. Heggelund J., Hoff J., Helgerud J., Nilsberg G.E., Morken G. Reduced peak oxygen uptake and implications for cardiovascular health and quality of life in patients with schizophrenia. BMC Psychiatry. 2011;11:188. doi: 10.1186/1471-244X-11-188.
    1. Nygard M., Brobakken M.F., Roel R.B., Taylor J.L., Reitan S.K., Guzey I.C., Morken G., Vedul-Kjelsas E., Wang E., Heggelund J. Patients with schizophrenia have impaired muscle force-generating capacity and functional performance. Scand. J. Med. Sci. Sports. 2019;29:1968–1979. doi: 10.1111/sms.13526.
    1. Bonett D.G. Sample size requirements for testing and estimating coefficient alpha. J. Educ. Behav. Stat. 2002;27:335–340. doi: 10.3102/10769986027004335.
    1. Yurdugül H. Minimum sample size for Cronbach’s coefficient alpha: A Monte-Carlo study. Hacet. Üniversitesi Eğitim Fakültesi Derg. 2008;35:1–9.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit